Capricor Therapeutics earnings release, August 13, 2026

Capricor Therapeutics, Inc. (CAPR) · Form 8-K, Item 2.02 · Filed · SEC filing

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics

(NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“Our priority is, and always has been, to get Deramiocel to the patients and families living with Duchenne who need it most,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. “The Advisory Committee outcome was not the one we hoped for. The indication we requested in 2024 was the treatment of cardiomyopathy in DMD, and that is the question the Committee was asked to vote on, not the HOPE-3 primary endpoint. HOPE-3 was designed and powered to demonstrate efficacy in upper limb function; cardiac function was a key secondary endpoint, measured across all patients enrolled rather than only those with established cardiomyopathy. The full dataset has since been published in The Lancet following extensive and independent peer review, and we continue to believe there is a path to approval for Deramiocel.”

Dr. Marbán continued, “The most powerful part of the Advisory Committee was the open public hearing, where patients, families and clinicians described what this therapy has meant, or could mean, to them. That testimony is on the public record, and it is a reminder of how urgent the unmet need in Duchenne remains. We are continuing to work with the Agency on a path forward.”

Second Quarter 2026 and Recent Highlights

Second Quarter 2026 Financial Results

Upcoming Investor Events

Conference Call and Webcast

To participate in the conference call, please dial 1-800-717-1738 (Domestic) or 1-646-307-1865 (International) and reference the conference ID: 91880. Participants may dial in using the numbers above and ask to be joined to the call or click the

Call Me™ link for instant telephone access to the event. To participate via a webcast, please click here. A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website.

About Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. There is no cure, and treatment options remain limited.

About Deramiocel

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. CDCs have been investigated in more than 250 peer-reviewed scientific publications and administered to over 250 human subjects across multiple clinical trials.

Deramiocel has received Orphan Drug Designation for the treatment of DMD from both the U.S. FDA and the European Medicines Agency (EMA). In addition, it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA, which may qualify Capricor for a Priority Review Voucher upon approval.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on

Facebook,

Instagram and

X.

Financial statements

Income Statement

Three Months Ended June 30, — (UNAUDITED)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
REVENUERevenue$—$—$—$—
OPERATING EXPENSESResearch and development28,866,29222,047,25456,243,20440,962,826
OPERATING EXPENSESGeneral and administrative14,079,3285,670,28023,475,26911,737,656
OPERATING EXPENSESTOTAL OPERATING EXPENSES42,945,62027,717,53479,718,47352,700,482
OPERATING EXPENSESLOSS FROM OPERATIONS-42,945,620-27,717,534-79,718,473-52,700,482
OTHER INCOME (EXPENSE)Other income2,27114,991-70,727-123,197
OTHER INCOME (EXPENSE)Investment income2,211,2951,793,3525,115,8012,522,894
OTHER INCOME (EXPENSE)TOTAL OTHER INCOME (EXPENSE)2,213,5661,808,3435,045,0742,399,697
OTHER INCOME (EXPENSE)LOSS BEFORE INCOME TAXES-40,732,054-25,909,191-74,673,399-50,300,785
OTHER INCOME (EXPENSE)(Provision for) benefit from income taxes-1,600-1,600-1,600-1,600
OTHER INCOME (EXPENSE)NET LOSS-40,733,654-25,910,791-74,674,999-50,302,385
OTHER COMPREHENSIVE INCOME (LOSS)Net unrealized gain (loss) on marketable securities90,186-424,353-446,695360,619
OTHER COMPREHENSIVE INCOME (LOSS)COMPREHENSIVE LOSS-40,643,468-26,335,144-75,121,694-49,941,766
OTHER COMPREHENSIVE INCOME (LOSS)Net loss per share, basic and diluted-0.7-0.57-1.29-1.1
OTHER COMPREHENSIVE INCOME (LOSS)Weighted average number of shares, basic and diluted57,926,34745,709,07157,681,66645,673,075

Balance Sheet

June 30, 2026 — SUMMARY BALANCE SHEETS

June 30, 2026 – (unaudited)December 31, 2025
Cash, cash equivalents and marketable securities237,934,782318,128,915
Total assets368,735,835355,949,294
Total liabilities122,516,94550,157,149
Total stockholders’ equity - 58,108,989 and 57,370,909 common shares issuedand outstanding at June 30, 2026 and December 31, 2025, respectively246,218,890305,792,145
Total stockholders’ equity - 58,108,989 and 57,370,909 common shares issuedTotal liabilities and stockholders’ equity368,735,835355,949,294
Full release

Cautionary Note Regarding Forward-Looking Statements... (truncated)xisting distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on May 13, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:

Caitlin Kasunich / Raquel Cona

KCSA Strategic Communications ckasunich@kcsa.com / rcona@kcsa.com

212.896.1241 / 516.779.2630

​

Capricor Company Contact:

AJ Bergmann, Chief Financial Officer abergmann@capricor.com

858.727.1755

​

​

​

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Capricor Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.